These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21196585)

  • 1. Use of adalimumab in treatment of autoimmune sensorineural hearing loss: a word of caution.
    Conway R; Khan S; Foley-Nolan D
    J Rheumatol; 2011 Jan; 38(1):176; author reply 176. PubMed ID: 21196585
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful use of adalimumab for treating rheumatoid arthritis with autoimmune sensorineural hearing loss: two birds with one stone.
    Morovic Vergles J; Radic M; Kovacic J; Salamon L
    J Rheumatol; 2010 May; 37(5):1080-1. PubMed ID: 20439536
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term efficacy of infliximab in autoimmune sensorineural hearing loss associated with rheumatoid arthritis.
    Gazeau P; Saraux A; Devauchelle-Pensec V; Cornec D
    Rheumatology (Oxford); 2014 Sep; 53(9):1715-6. PubMed ID: 24625506
    [No Abstract]   [Full Text] [Related]  

  • 4. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy.
    Nagashima T; Minota S
    J Rheumatol; 2011 Mar; 38(3):574; author reply 575. PubMed ID: 21362792
    [No Abstract]   [Full Text] [Related]  

  • 5. Pseudolymphomatoid cutaneous leishmaniasis in a patient treated with adalimumab for rheumatoid arthritis.
    Baltà-Cruz S; Alsina-Glbert M; Mozos-Rocafort A; Cervera C; Colomo-Saperas L; Del Río A; Estrach-Panella T
    Acta Derm Venereol; 2009; 89(4):432-3. PubMed ID: 19688168
    [No Abstract]   [Full Text] [Related]  

  • 6. Mycobacterium chelonae infection associated with adalimumab therapy.
    Díaz F; Urkijo JC; Mendoza F; de la Viuda JM; Blanco M; Unzurrunzaga A; Ayarza R
    Scand J Rheumatol; 2008; 37(2):159-60. PubMed ID: 18415777
    [No Abstract]   [Full Text] [Related]  

  • 7. Dermatomyositis during adalimumab therapy for rheumatoid arthritis.
    Brunasso AM; Scocco GL; Massone C
    J Rheumatol; 2010 Jul; 37(7):1549-50. PubMed ID: 20595297
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of alopecia areata universalis in a patient receiving adalimumab.
    Garcia Bartels N; Lee HH; Worm M; Burmester GR; Sterry W; Blume-Peytavi U
    Arch Dermatol; 2006 Dec; 142(12):1654-5. PubMed ID: 17179003
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma.
    Liozon E; Ouattara B; Loustaud-Ratti V; Vidal E
    Scand J Rheumatol; 2007; 36(6):484-6. PubMed ID: 18092275
    [No Abstract]   [Full Text] [Related]  

  • 10. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
    van Rijthoven AW; Bijlsma JW; Canninga-van Dijk M; Derksen RH; van Roon JA
    Rheumatology (Oxford); 2006 Oct; 45(10):1317-9. PubMed ID: 16844698
    [No Abstract]   [Full Text] [Related]  

  • 11. Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab).
    Chaves Y; Duarte G; Ben-Said B; Tebib J; Berard F; Nicolas JF
    Dermatology; 2008; 217(4):380. PubMed ID: 18849606
    [No Abstract]   [Full Text] [Related]  

  • 12. Systemic listeriosis with adalimumab therapy.
    Murphy G; Schmidt-Martin D; Hynes BG; Harney S
    J Clin Rheumatol; 2009 Oct; 15(7):369-70. PubMed ID: 20009978
    [No Abstract]   [Full Text] [Related]  

  • 13. Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon?
    Stichenwirth M; Riedl E; Pehamberger H; Tappeiner G
    Arch Dermatol; 2008 Jun; 144(6):817-8. PubMed ID: 18559788
    [No Abstract]   [Full Text] [Related]  

  • 14. Adalimumab-associated multiple sclerosis.
    Bensouda-Grimaldi L; Mulleman D; Valat JP; Autret-Leca E
    J Rheumatol; 2007 Jan; 34(1):239-40; discussion 240. PubMed ID: 17216704
    [No Abstract]   [Full Text] [Related]  

  • 15. Tuberculous peritonitis after treatment with adalimumab.
    Antolín J; Azahara M; Hernández C; Blanco M; Mao L; Cigüenza R
    Scand J Infect Dis; 2008; 40(8):677-8. PubMed ID: 18979608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)].
    Hirohata S
    Nihon Rinsho; 2007 Jul; 65(7):1202-8. PubMed ID: 17642233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morbidity and mortality in rheumatoid patients during treatment with adalimumab and infliximab.
    Molloy E; Ramakrishnan S; Murphy E; Barry M
    Rheumatology (Oxford); 2004 Apr; 43(4):522-3. PubMed ID: 15024136
    [No Abstract]   [Full Text] [Related]  

  • 19. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
    Burmester GR; Mariette X; Montecucco C; Monteagudo-Sáez I; Malaise M; Tzioufas AG; Bijlsma JW; Unnebrink K; Kary S; Kupper H
    Ann Rheum Dis; 2007 Jun; 66(6):732-9. PubMed ID: 17329305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced lupus erythematosus in a patient treated with adalumimab.
    Spillane AP; Xia Y; Sniezek PJ
    J Am Acad Dermatol; 2007 May; 56(5 Suppl):S114-6. PubMed ID: 17434034
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.